antazoline

DRUG2 trials

Sponsors

National Institute of Cardiology, Warsaw, Poland, Centre of Postgraduate Medical Education

Conditions

Atrial FibrillationParoxysmal Atrial Fibrillation

Phase 4

Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation

CompletedNCT01527279

National Institute of Cardiology, Warsaw, PolandParoxysmal Atrial Fibrillation

Start: 2012-11-30End: 2015-03-31Updated: 2015-05-22

Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.

Centre of Postgraduate Medical EducationAtrial Fibrillation

Start: 2019-09-01End: 2026-01-01Target: 105Updated: 2023-02-14

Related Papers

Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study)

EP Europace2016-11-0231 citations

Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

2012-09-1111 citations